Author

Alysha Barbera

Observed name: A. Barbera

Observed institutions: IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola, University of Bologna

OpenAlex ID: A5048196154

Updated safety of midostaurin plus chemotherapy in newly diagnosed FLT3 mutation–positive acute myeloid leukemia: the RADIUS-X expanded access program

2020 · Gail J. Roboz, Stephen A. Strickland, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 20

Midostaurin in Adults with Newly Diagnosed FLT3-Mutation-Positive Acute Myeloid Leukemia Eligible for Standard Chemotherapy: Update from the Radius-X Midostaurin Expanded Access Program

2018 · Alexander E. Perl, Kendra L. Sweet, et al. · Blood · 2

RADIUS-X: An Expanded Treatment Protocol for Midostaurin in Combination with Standard Chemotherapy in Adults with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia

2018 · Gail Roboz, Stephen Strickland, et al. · Clinical Lymphoma Myeloma & Leukemia

Second-line chemotherapy (CT2) in advanced biliary tract cancer (aBTC) patients (pts) progressed to first-line chemotherapy (CT1) with gemcitabine plus platinum: where are we now?

2015 · L. Fornaro, S. Cereda, et al. · Annals of Oncology

Works count: 4

Citation count: 22

H-index: 2

I10-index: 1